Beyond Biotech podcast 47

Photo/Shutterstock
Beyond Biotech podcast 47

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*
This field is for validation purposes and should be left unchanged.

The companies Daiichi Sankyo and AstraZeneca have worked together for several years.

This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca.

On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining forces to bring new oncology medicines into clinical practice.

In March 2019, AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize health technologies worldwide. Their collaboration is designed to leverage strengths and combine efforts to improve patient care.

Partnering 2030: The Biotech Perspective 2023

Download Inpart’s latest report revealing the priorities of out-licensers worldwide.